All questionsSpecific populations: Trodelvy (sacituzumab govitecan-hziy) in metastatic triple-negative breast cancer2 questions · 1 sourceSpecific populationsCan TRODELVY be used during pregnancy?“Embryo-Fetal Toxicity: Based on its mechanism of action, TRODELVY can cause teratogenicity and/or embryo-fetal lethality when administered to a pregnant woman. TRODELVY contains a genotoxic component, SN-38, and targets rapidly dividing cells. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.” (opens the source at this quote in a new tab)CopyFlagHow long is contraception needed after TRODELVY?“Advise females of reproductive potential to use effective contraception during treatment with TRODELVY and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with TRODELVY and for 3 months after the last dose.” (opens the source at this quote in a new tab)CopyFlag